As the Medicare program struggles to control expenditures, there is increased focus on opportunities to manage patient populations more efficiently and at a lower cost. A major source of expense for the Medicare program is beneficiaries at end of life. Estimates of the percentage of Medicare costs that arise from patients in the last year of life differ, ranging from 13% to 25%, depending on methods and assumptions. We analyze the most recently available Medicare Limited Data Set to update prior studies of end-of-life costs and examine different methods of performing this calculation. Based upon these findings, we conclude that higher estimates that take into account the spending over the 12 months leading up to death more accurately reflect the full cost of a patient's last year of life. Comparing current year costs of decedents with Medicare's current year costs understates the full budgetary impact of endof-life patients. Because risk-taking entities such as Medicare Advantage plans and Accountable Care Organizations (ACOs) need to reduce costs while improving the quality of care, they should initiate programs to better manage the care of patients with serious or advanced illness. We also calculate costs for beneficiaries dying in different settings and conclude that more effective use of palliative care and hospice benefits offers a lower cost, higher quality alternative for patients at end of life.
Background
As the Medicare program struggles to control expenditures, there is increased focus on opportunities to manage patient populations more efficiently and at a lower cost. Patients at end of life (EOL) represent a disproportionate share of Medicare's costs, implying that these patients are an appropriate population for management by risk-taking Medicare entities such as Medicare Advantage plans and Accountable Care Organizations (ACOs), whose mission is to reduce cost as well as improve the quality of care. Because risk-taking entities need to reduce costs to share savings, they seek opportunities for more intense patient engagement and management. Actuaries, health economists, policy analysts, and health services researchers have studied expenditures at the EOL for Medicare decedents for more than 30 years. What is important from the perspective of managing patients and costs is that for patients at the EOL, alternative care pathways that involve palliative care are available which can result in higher quality of life at less cost.
The objectives of this article are 4-fold:
EOL costs and utilization patterns, we summarize examples of different aspects, as well as some recent developments in palliative care, quality, and futile care. Numerous articles on EOL costs show that a large proportion of Medicare expenditures occur during the last 6 months of life. [1] [2] [3] [4] [5] [6] [7] [8] [9] This phenomenon has continued for many years as the number of Medicare decedents has increased with the aging American population. Medicare expenditures for EOL have increased dramatically from 1983 to 2016, primarily because of the increase in the number of decedents. Other articles compare EOL expenditures in the United States to other countries 10, 11 or focus on Medicare expenditures for specific diseases. [12] [13] [14] A recent development in the literature challenges the idea that EOL costs are responsible for a high percentage of health-care costs. 15 Below, we discuss methodological differences that could account for differences in estimated proportions. Utilization trends also affect Medicare expenditures and utilization patterns at the EOL, including a higher proportion of Medicare decedents electing hospice. In addition, an increasing proportion of Medicare decedents electing hospice are living longer than 6 months, and noncancer patients now constitute the majority of hospice patients.
Cost Savings
Several researchers have studied the hypothesis that hospice care reduces Medicare expenditures. [16] [17] [18] Although the evidence is mixed, recent research challenges this hypothesis, although methodological issues make testing difficult. 19 Hospice eligibility is based upon a prognosis of 6 months or less, but predicting the remaining length of life for most terminally ill patients is difficult, especially for those with noncancer diagnoses. The Centers for Medicare and Medicaid Services (CMS) reimburses hospices on a per diem basis for all care related to the terminal prognosis, including nursing care, social services, spiritual care, medications, medical equipment, personal aides, volunteers, and bereavement services. Based upon a per diem payment system, patients with long lengths of stay in hospice are less likely to create savings. 20 The patient's diagnosis is an important variable. [21] [22] [23] [24] [25] Several innovative programs have been tried to alter the payment methods for the delivery of hospice services designed to improve the coordination of EOL care and better control of EOL costs. Descriptions of experimental and successful palliative care programs are provided in the March 2018 MedPAC report and several other references. 19, [26] [27] [28] [29] [30] Finally, physicians have noted that some care, particularly in acute hospitals, is futile. Attempts to define, identify, and address such care is in its infancy.
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Data/Methods
The Medicare 5% LDS Analytical File ("Medicare 5% File") 32 and Medicare's published rate. Deaths are assigned to a particular place of death based on the last service date. For deaths reported in the eligibility file, the service with the latest reported date determines the place of death. We calculated the Medicare expenditures for inpatient, outpatient, professional, emergency department, physician office visits, hospital outpatient visits, hospice, skilled mursing facility, home health, and durable medical supplies. Outpatient pharmaceutical data are not included in the 5% files, although inpatient and outpatient infused drugs are paid under Medicare Part B and are included.
Results
Medicare Costs at EOL
The share of Medicare's total costs represented by subpopulations helps identify areas of opportunity for program management. There is some controversy over the share of Medicare's cost that Medicare decedents represent. A defined period, usually the last 12 months of life, is essential for assessing the cost of EOL patients because of the exponential increase in cost in the last months of life (see, eg, Table 1 ). However, some comparisons are made on a calendar period basis, which (by definition) includes patients with differing life expectancies. A typical statistic is that 25% of all Medicare's annual costs are accounted for by decedents (Riley and Lubitz 1 based on 2006 Medicare payments). Cubanski et al in a 2016 Kaiser Family Foundation Data Note 33 report that "in 2014, beneficiaries who died at some point during the year accounted for 4% of all beneficiaries in traditional Medicare, but 13.5% of traditional Medicare spending . . . This estimate is lower than the 25% estimate cited earlier because it is based on Medicare spending for people who died at some point in a given CY (in this case, 2014), rather than the last 12 months of spending for people who died." Aldridge and Kelley 15 also challenge the traditional estimate from the perspective of total EOL spending in the population (not restricted to Medicare patients). They report 13% of total spending due to patients in the last year of life. French et al 34 compare international costs at EOL, reporting 8.5% for the United States. Finally, a recent article by Finkelstein et al, 35 using Medicare data from 2007 to 2008, reports that patients dying in 2008 accounted for 15% of total Medicare cost for that year. Whether total spending on EOL patients is 13% or closer to 25% matters in terms of the priority given to managing this subpopulation.
Medicare's cost in the last 12 months of EOL patients can be estimated on a current cost basis, by dividing the cost of those members who die in a year by Medicare's total cost in the year.
As we show in Table 2 , allowed cost for those members who died in 2015 is US$2.5 billion; total allowed cost for 2015 amounted to US$19.0 billion, resulting in a share of decedents of 13.4%. However, this current cost basis overlooks 2 important adjustments that are necessary to estimate accurately the cost of decedents that takes their final 12 months of costs into consideration: 
Costs by Type of Service
In order to model the opportunity for Medicare Advantage plans and MSSP ACOs through reducing the cost of EOL care, we investigate recent Medicare EOL expenditures by type of service, using the most recent Medicare LDS data for CY 2015 to 2016. Table 1 shows an analysis of Medicare's cost per decedent by type of service during the 90 and 180 days prior to death, according to the place of death.
Average Medicare expenditures per decedent per month are greater in the last 90 days preceding death versus the last 180 days preceding death, confirming the exponential increase in costs as death approaches. The highest spending occurs in acute hospitals. Care provided in skilled nursing, hospice, and home health care are other major sources of Medicare expenditures. An increasing proportion of Medicare decedents' final care is rendered by hospices. Average Medicare expenditures per decedent per month increased by 2% from 2015 to 2016.
It might be expected that the mean expenditure is influenced by "outliers," which we define as beneficiaries with Medicare expenditures above or below 3.0 Â (Q3 À Q1), where (Q3 À Q1) is the interquartile range. However, the results shown in Table 3 , when compared to Table 4 , show relatively little effect on average Medicare payments of removing outliers, implying that people with very high costs are relatively few among all decedents. Table 5 displays the average Medicare expenditures for patients treated in acute hospitals during the last 180 days of life, compared to the hospice per diem cost. The cost of patients treated in the inpatient setting far exceeds the per diem expenditure for palliative or hospice care. Key to the estimation of potential savings from earlier hospice referral is the reimbursement rates paid by CMS. 36 For Fiscal Year 2017 (October 2016 to September 2017), the base rate was US$190.55; for the last 7 days of life, this rate is boosted by a service intensity add-on of US$40.19. For the last 7 days of life, total reimbursement is US$230.74. Thus, savings are possible from admission to hospice within 90 days of death, based on the lower hospice reimbursement rate compared to the average cost of a patient who dies in hospital. With 25% of all Medicare beneficiaries dying in inpatient hospitals, the savings from increased hospice use could be considerable. One challenge, as described by Finkelstein et al, 35 is identifying patients who could be eligible for Medicare expenditures increase sharply in the last few days of life, particularly for patients who die in hospital. Recent developments in hospice and palliative care offer the possibility of higher quality care at lower cost to Medicare if patients enter hospice earlier. Finding a lower cost site of care that does not jeopardize patients' wishes is a realistic, worthy goal. Expensive, futile care-especially given in an intensive care unit of an acute hospital-probably does not meet the preferences of most people at the end of life. Identifying those who will benefit from intensive care from those in which aggressive care is likely to be futile and burdensome is a challenge for providers, patients, and families. Published studies show that palliative care services can have a moderating effect on cost while improving quality of care. Examples of studies include the study by Lustbader et al, Center to Advance Palliative Care, and Pham and Krahn, and Smith et al. [37] [38] [39] [40] The increased existence of hospital-based palliative care services and the recent development of communitybased palliative care programs may help to ensure that care at the EOL is concordant with patient and family goals, while at the same reducing the cost of care.
Conclusion
Beneficiaries at EOL account for a significant portion of Medicare spending. Comparing current year cost of decedents with Medicare's current year costs understates the full budgetary impact of EOL patients. Greater use of hospice and palliative care, with their lower cost per patient, offers the possibility of expense reduction to the Medicare program while also improving quality of life outcomes.
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